Cargando…
KRAS inhibitors: going noncovalent
KRAS (G12D) is the most frequent KRAS mutation in human cancer with particularly high frequencies in pancreatic and colorectal cancer. Informed by the structure of the KRAS(G12C) inhibitor adagrasib, Hallin et al. have now, through multiple rounds of structure‐based drug design, identified and valid...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718111/ https://www.ncbi.nlm.nih.gov/pubmed/36383067 http://dx.doi.org/10.1002/1878-0261.13341 |